Crescent Biopharma, Inc.
CBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001253689
In the last 90 days, Crescent Biopharma, Inc. insiders filed 1 open-market purchase and 7 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $532.6M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $12.4M in total
- 1
- Insider sellsLast 90 days, $285.5K in total
- 7
- 13F holdersQ2 2026, +19 vs. previous quarter
- 82
- 13F valueReported value at the end of Q2 2026
- $532.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CBIO, Q2 2026
No superinvestor reported holding CBIO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Crescent Biopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:03 PM ET | Sep 16 | 2 days | Lynch RyanSee Remarks | SSale | −240 | $17.90 | −$4.30K | −1.7%13.6K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:03 PM ET | Sep 16 | 2 days | Pinkas JanChief Scientific Officer | SSale | −658 | $17.90 | −$11.8K | −3.0%21.6K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16 | 2 days | Im Ellie EunkyungChief Medical Officer | SSale | −623 | $17.90 | −$11.2K | −2.8%21.4K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16 | 2 days | Scalzo Richard WilliamChief Financial Officer | SSale | −568 | $17.90 | −$10.2K | −2.8%19.7K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16 | 2 days | Bispham Barbara HarlinSee Remarks | SSale | −620 | $17.90 | −$11.1K | −3.2%18.7K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:02 PM ET | Sep 16-18 | 2 days | Brumm Joshua TChief Executive Officer | SSale | −9.45K | $16.91 | −$159.8K | −3.4%271.8K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)4:01 PM ET | Sep 16-18 | 2 days | McNeill JonathanPresident and COO | SSale | −4.57K | $16.90 | −$77.2K | −3.3%134.6K after | 2 lots10b5-1 |
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +853.5K | $14.50 | +$12.4M | +31.1%3.60M after | |
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +525.9K | $14.50 | +$7.62M | –2.29M after | Derivative |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Lynch RyanSee Remarks | SSale | −465 | $17.99 | −$8.37K | −3.2%13.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Crescent Biopharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 4,133,514 | $74.4M | 0.00% | 00.0% | Unchanged |
| BVF Inc | 2,748,763 | $49.5M | 1.27% | 00.0% | Unchanged |
| Fairmount Funds Management LLC | 2,747,866 | $49.5M | 3.27% | 00.0% | Unchanged |
| VR Adviser, LLC | 2,133,576 | $38.4M | 1.16% | 00.0% | Unchanged |
| Logos Global Management LP | 1,900,000 | $34.2M | 1.47% | +1,417,500+293.8% | Added |
| FCPM III Services B.V. | 1,677,852 | $30.2M | 4.02% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 1,662,917 | $29.9M | 0.05% | +152,884+10.1% | Added |
| Vestal Point Capital, LP | 1,630,000 | $29.3M | 0.69% | +130,000+8.7% | Added |
| Opaleye Management Inc. | 1,319,351 | $23.7M | 2.15% | +6,736+0.5% | Added |
| BlackRock, Inc. | 1,271,762 | $22.9M | 0.00% | +1,156,037+999.0% | Added |